Kwality Pharmaceuticals (539997) Q2 24/25 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and half-year ended 30th September 2024 were reviewed and approved by the Board on 30th October 2024.

• Statutory auditors issued limited review reports with no material misstatements identified in both standalone and consolidated statements.

Financial highlights

• Standalone revenue from operations for Q2 FY25 was ₹9,003.44 lakhs, up from ₹6,964.95 lakhs in Q2 FY24; half-year revenue reached ₹17,011.33 lakhs.

• Standalone net profit after tax for Q2 FY25 was ₹848.52 lakhs, compared to ₹625.71 lakhs in Q2 FY24; half-year net profit was ₹1,685.21 lakhs.

• Consolidated revenue from operations for Q2 FY25 was ₹9,003.44 lakhs, with consolidated net profit after tax at ₹845.55 lakhs for the quarter.

• Basic and diluted EPS for Q2 FY25 stood at ₹8.18 (standalone) and ₹8.15 (consolidated), up from ₹6.03 and ₹5.99 respectively in Q2 FY24.

Outlook and guidance

• The company continues to focus on its core pharmaceutical business, with no separate segment reporting as it operates in a single segment.